Video Gallery

About this Video

Mr. Stéphane Bancel joined Moderna in the summer of 2011 when it was a one employee company. He has assembled a world-class team and raised more than $1Billion between equity financing and upfront from licensing collaborations. Hear directly from Mr. Bancel about what it takes to be CEO of such a rapidly growing company.

Stéphane Bancel is the CEO of Moderna, a pharmaceutical company that is pioneering the development of a new class of drugs made of messenger RNA (mRNA). He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMerieux has more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion. He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Mr. Bancel was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for investor relations in France in 2009 and was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. Mr. Bancel serves as a supervisory director of Qiagen N.V., and on the Board of Directors of Syros Pharmaceuticals.

About the Speaker

Stephane Bancel

Stephane Bancel

Stephane Bancel

Stéphane has served as Moderna’s chief executive officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as chief executive officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as managing director for Belgium and as executive director of global manufacturing strategy and supply chain. Prior to his work at Lilly, Stéphane served as Asia-Pacific sales and marketing director for bioMérieux. Stéphane currently serves on the board of directors of Generate Biomedicines and Qiagen N.V., and he previously served on the boards of BG Medicine, Inc. and Syros Pharmaceuticals, Inc. (Nasdaq: SYRS). He is a venture partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Stéphane holds a master of engineering degree from École Centrale Paris (ECP), a master’s of science in chemical engineering from the University of Minnesota, and an MBA from Harvard Business School.